Patents by Inventor Brett Granger

Brett Granger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240132476
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: October 25, 2023
    Publication date: April 25, 2024
    Inventors: Guoqiang Wang, Ruichao Shen, Brett Granger, Jing He, Xuechao Xing, Yong He, Jiang Long, Jun Ma, Bin Wang, Yat Sun Or
  • Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
    Patent number: 11958879
    Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: April 16, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He
  • Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 11834436
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: December 5, 2023
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Ruichao Shen, Brett Granger, Jing He, Xuechao Xing, Yong He, Jiang Long, Jun Ma, Bin Wang, Yat Sun Or
  • APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230174515
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Application
    Filed: December 2, 2022
    Publication date: June 8, 2023
    Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
  • 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230143250
    Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions comprising these compounds and methods of using these compounds to provides a method of modulating a HSD17B13 protein for treatment of metabolic disease or liver condition, The present invention relates generally to compounds and pharmaceutical compositions useful as 17?-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17?-HSD13 and methods for their preparation and use.
    Type: Application
    Filed: August 19, 2022
    Publication date: May 11, 2023
    Inventors: Guoqiang Wang, Jun Ma, Brett Granger, Jiang Long, Bin Wang, Sourav Ghorai, Jing He, Yong He, Xuechao Xing, Ruichao Shen, Yat Sun Or
  • Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 11560368
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: January 24, 2023
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
  • BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20220402966
    Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Application
    Filed: May 19, 2021
    Publication date: December 22, 2022
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He
  • APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220356167
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Application
    Filed: March 10, 2021
    Publication date: November 10, 2022
    Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
  • Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
    Patent number: 11466033
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: October 11, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brett Granger, Yong He, Guoqiang Wang, Yat Sun Or
  • Heterocyclic compounds as anti-viral agents
    Patent number: 11420976
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: August 23, 2022
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Yong He, Xuechao Xing, Guoqiang Wang, Ruichao Shen, Brett Granger, Jiang Long, Yat Sun Or
  • Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 11345699
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: May 31, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brett Granger, Guoqiang Wang, Ruichao Shen, Jing He, Yong He, Xuechao Xing, Jun Ma, Jiang Long, Bin Wang, Yat Sun Or
  • TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220119366
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: April 13, 2021
    Publication date: April 21, 2022
    Inventors: Guoqiang Wang, Ruichao Shen, Brett Granger, Jing He, Xuechao Xing, Yong He, Jiang Long, Jun Ma, Bin Wang, Yat Sun Or
  • HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS
    Publication number: 20210238188
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: January 22, 2021
    Publication date: August 5, 2021
    Inventors: Yong He, Xuechao Xing, Guoqiang Wang, Ruichao Shen, Brett Granger, Jiang Long, Yat Sun Or
  • Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
    Patent number: 11040998
    Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: June 22, 2021
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He
  • Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 11008304
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: May 18, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Ruichao Shen, Brett Granger, Jing He, Xuechao Xing, Yong He, Jiang Long, Jun Ma, Bin Wang, Yat Sun Or
  • Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 10988458
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: April 27, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
  • Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 10968199
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof, which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: April 6, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jing He, Brett Granger, Guoqiang Wang, Yat Sun Or
  • Process for preparation of sulfonyl carbamate bile acid derivatives
    Patent number: 10961272
    Abstract: The present invention relates to processes for preparing compounds of Formula (I) and Formula (II): These compounds are useful as FXR or TGR5 modulators.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: March 30, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yong He, Brett Granger, Xuechao Xing, Yat Sun Or
  • APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20200331890
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Application
    Filed: May 5, 2020
    Publication date: October 22, 2020
    Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
  • PROCESS FOR PREPARATION OF SULFONYL CARBAMATE BILE ACID DERIVATIVES
    Publication number: 20200317717
    Abstract: The present invention relates to processes for preparing compounds of Formula (I) and Formula (II): These compounds are useful as FXR or TGR5 modulators.
    Type: Application
    Filed: April 21, 2020
    Publication date: October 8, 2020
    Inventors: Guoqiang Wang, Yong He, Brett Granger, Xuechao Xing, Yat Sun Or